Literature DB >> 20507872

The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus.

E J Córdova1, R Velázquez-Cruz, F Centeno, V Baca, L Orozco.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease associated with oxidative stress and characterized by chronic inflammation. Kidney malfunction, an aggressive characteristic of this disease, is not present in all affected individuals. The Nrf2-Keap1 pathway is important in protecting against oxidative stress and inflammation. Mouse models and genome-wide scans have suggested NRF2 (Nuclear factor (erythroid-derived 2)-like 2) as a candidate gene for susceptibility to SLE. We therefore investigated whether NRF2 polymorphisms are associated with childhood-onset SLE in a Mexican Mestizo population. Two single nucleotide polymorphisms (SNPs) were genotyped by TaqMan((R)) assays in 362 patients with childhood-onset SLE and 379 controls. We found no significant association between susceptibility to SLE and NRF2 polymorphisms. However, after population stratification by gender, the heterozygous genotype of the -653G/A SNP was significantly associated with nephritis in females only [OR = 1.81, CI (1.04-3.12), p = 0.032]. This association was stronger in females affected with severe nephritis [classes IV-VI; OR = 2.16, CI (1.12-4.15), p = 0.019]. Our results suggest that NRF2 is not associated with susceptibility to childhood-onset SLE, but it could confer a risk for developing kidney malfunction in SLE-affected individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20507872     DOI: 10.1177/0961203310367917

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  28 in total

1.  Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans.

Authors:  Ewa D Marczak; Jacqui Marzec; Darryl C Zeldin; Steven R Kleeberger; Nancy J Brown; Mias Pretorius; Craig R Lee
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

Review 2.  Nrf2: a potential target for new therapeutics in liver disease.

Authors:  A M Bataille; J E Manautou
Journal:  Clin Pharmacol Ther       Date:  2012-08-08       Impact factor: 6.875

3.  Association of Nrf2 polymorphism haplotypes with acute lung injury phenotypes in inbred strains of mice.

Authors:  Hye-Youn Cho; Anne E Jedlicka; Wesley Gladwell; Jacqui Marzec; Zackary R McCaw; Rachelle J Bienstock; Steven R Kleeberger
Journal:  Antioxid Redox Signal       Date:  2014-11-12       Impact factor: 8.401

4.  Enhancing the Nrf2 Antioxidant Signaling Provides Protection Against Trichloroethene-mediated Inflammation and Autoimmune Response.

Authors:  Nivedita Banerjee; Hui Wang; Gangduo Wang; M Firoze Khan
Journal:  Toxicol Sci       Date:  2020-05-01       Impact factor: 4.849

Review 5.  Interaction between glutathione and apoptosis in systemic lupus erythematosus.

Authors:  Dilip Shah; Sangita Sah; Swapan K Nath
Journal:  Autoimmun Rev       Date:  2012-12-29       Impact factor: 9.754

6.  Genetic variation at a Yin-Yang 1 response site regulates the transcription of cyclin-dependent kinase inhibitor p18INK4C transcript in lupus-prone mice.

Authors:  Hari-Hara S K Potula; Laurence Morel
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

7.  Environmental Agents, Oxidative Stress and Autoimmunity.

Authors:  M Firoze Khan; Gangduo Wang
Journal:  Curr Opin Toxicol       Date:  2017-10-26

Review 8.  Functional polymorphisms in Nrf2: implications for human disease.

Authors:  Hye-Youn Cho; Jacqui Marzec; Steven R Kleeberger
Journal:  Free Radic Biol Med       Date:  2015-06-25       Impact factor: 7.376

9.  Th2 skewing by activation of Nrf2 in CD4(+) T cells.

Authors:  Cheryl E Rockwell; Mingcai Zhang; Patrick E Fields; Curtis D Klaassen
Journal:  J Immunol       Date:  2012-01-16       Impact factor: 5.422

Review 10.  Oxidative stress in the pathology and treatment of systemic lupus erythematosus.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2013-10-08       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.